Follow

Lytix Biopharma AS

Euronext Growth Oslo (Norway)

Lytix Biopharma is a clinical stage biotech company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic peptide with the potential to personalize immunotherapy.

Sector:
HEALTH CARE
>
Biotechnology
Pharmaceuticals And Biotechnology
News
01 May 2018 - 23:00
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
LYTIX
NO0010405780
Euronext Growth Oslo
Norway (NO)
Details of share in Lytix Biopharma AS with ticker LYTIX
Status
Active
Order book id
Amount of instruments
Par value
Currency
NOK
Type
Price
Pre-money
Time
Files
Listing
18.00 NOK
697.3M NOK
14 Jun 2021
Direct listing of Lytix Biopharma AS on Euronext Growth Oslo
People
Øystein Rekdal
CEO
Gert Wilhelm Munthe
Chairman of the board
Debasish Francois Roychowdhury
Board member
Per Erik Sørensen
Board member
Company Details
Sector
HEALTH CARE

Address
Hoffsveien 4
Zip code
0275
City/district
Oslo
Country
Norway (NO)
Registration number
985 889 635
LEI code
549300NXMIMRSBCDZO71
First trade date
Registration date
25 Aug 2003
Short name
Lytix

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More